MedPath
NMPA Approval

Irinotecan Hydrochloride Liposome Injection(Ⅱ)

国药准字H20230036

January 9, 2024

Drug Information

盐酸伊立替康脂质体注射液(Ⅱ)

注射剂

8ml:37.66mg(按C₃₃H₃₈N₄O₆计)

化学药品

January 9, 2024

Company Information

Applicant Company

连云港经济技术开发区黄河路38号

Manufacturing Company

连云港经济技术开发区临港产业区东晋路

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

盐酸伊立替康脂质体注射液(Ⅱ) - NMPA 批准文号 | MedPath